<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26671">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01818115</url>
  </required_header>
  <id_info>
    <org_study_id>CP-10-001</org_study_id>
    <nct_id>NCT01818115</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Trial to Evaluate the Hydrus(TM) Implant in Subjects Undergoing Cataract Surgery.</brief_title>
  <acronym>Hydrus II</acronym>
  <official_title>A Prospective, Multi-Center, Randomized Controlled Trial to Evaluate the Safety and Effectiveness of the Hydrus Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ivantis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ivantis, Inc.</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to demonstrate the ability of the Hydrus Implant to lower
      intraocular pressure in glaucoma patients undergoing cataract surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a post-market, prospective, single-masked, randomized, controlled, multicenter
      clinical trial comparing Cataract Extraction (CE) surgery + Hydrus Implant vs CE surgery
      alone for the reduction of intraocular pressure (IOP) in patients with a positive diagnosis
      for open angle glaucoma (POAG) or pseudoexfoliative glaucoma.  Eligible patients will be
      scheduled for cataract surgery.  At the time of the procedure, qualified subjects will be
      randomized into 1 of 2 treatment groups: Hydrus Implant with cataract surgery or cataract
      surgery alone.  Post-operative follow up will be conducted at regular intervals.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reduction in mean diurnal Intraocular Pressure (IOP) at 12 months following the wash-out of all glaucoma medications.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>A 24 month visit will be conducted to confirm 12 month findings.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of eyes with reduction in washed out IOP of at least 20% from baseline to 12 months.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>A 24 month visit will be conducted to confirm 12 month findings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Best-corrected Visual Acuity (BCVA) from baseline to 12 months as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>A 24 month visit will be conducted to confirm 12 month findings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of eyes with IOP &gt;5 mmHg to â‰¤19 mmHg following terminal washout.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>A 24 month visit will be conducted to confirm 12 month findings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diurnal IOP at 24 months following washout</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>A 24 month visit will be conducted to confirm 12 month findings</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Glaucoma, Open Angle, Pseudo-exfoliative</condition>
  <condition>Cataract Unilateral Pending Extraction</condition>
  <arm_group>
    <arm_group_label>IOL placement with Hydrus Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cataract extraction with intraocular lens (IOL) placement and Hydrus Implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IOL placement only.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cataract Extraction with IOL placement only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydrus Implant</intervention_name>
    <arm_group_label>IOL placement with Hydrus Implant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IOL placement</intervention_name>
    <arm_group_label>IOL placement only.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Primary Open Angle Glaucoma or Pseudoexfoliative Glaucoma.

          -  Operable, age-related cataract eligible for phacoemulsification.

        Exclusion Criteria:

          -  Closed Angle and narrow angle forms of Glaucoma.

          -  Other Secondary Glaucoma, (such as neovascular, uveitic, traumatic, steroid induced,
             lens induced); glaucoma associated with increase episcleral venous pressure;
             congenital or developmental glaucoma.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Norbert Pfeiffer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitatsmedizin Mainz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>See Central Contact</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>See Central Contact</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>See Central Contact</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>See Central Contact</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>See Central Contact</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>See Central Contact</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>See Central Contact</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 25, 2013</lastchanged_date>
  <firstreceived_date>February 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>POAG</keyword>
  <keyword>PXG</keyword>
  <keyword>IOL Surgery</keyword>
  <keyword>CE Surgery</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
